Mary Wilson
Well-known member
medRxiv preprint
this version posted June 16, 2022
doi: https://doi.org/10.1101/2022.06.14.22276401
Zoe Swank1,2,3, Yasmeen Senussi1,2,3, Galit Alter4, 5, David R. Walt1,2,3
Abstract
The diagnosis and management of post-acute sequelae of COVID-19 (PASC) poses an ongoing medical challenge. Identifying biomarkers associated with PASC would immensely improve the classification of PASC patients and provide the means to evaluate treatment strategies. We analyzed plasma samples collected from a cohort of PASC and COVID-19 patients (n = 63) to quantify circulating viral antigens and inflammatory markers. Strikingly, we detect SARS-CoV-2 spike antigen in a majority of PASC patients up to 12 months post-diagnosis, suggesting the presence of an active persistent SARS- CoV-2 viral reservoir. Furthermore, temporal antigen profiles for many patients show the presence of spike at multiple time points over several months, highlighting the potential utility of the SARS-CoV-2 full spike protein as a biomarker for PASC.
https://www.medrxiv.org/content/10.1101/2022.06.14.22276401v1.full.pdf
this version posted June 16, 2022
doi: https://doi.org/10.1101/2022.06.14.22276401
Zoe Swank1,2,3, Yasmeen Senussi1,2,3, Galit Alter4, 5, David R. Walt1,2,3
Abstract
The diagnosis and management of post-acute sequelae of COVID-19 (PASC) poses an ongoing medical challenge. Identifying biomarkers associated with PASC would immensely improve the classification of PASC patients and provide the means to evaluate treatment strategies. We analyzed plasma samples collected from a cohort of PASC and COVID-19 patients (n = 63) to quantify circulating viral antigens and inflammatory markers. Strikingly, we detect SARS-CoV-2 spike antigen in a majority of PASC patients up to 12 months post-diagnosis, suggesting the presence of an active persistent SARS- CoV-2 viral reservoir. Furthermore, temporal antigen profiles for many patients show the presence of spike at multiple time points over several months, highlighting the potential utility of the SARS-CoV-2 full spike protein as a biomarker for PASC.
https://www.medrxiv.org/content/10.1101/2022.06.14.22276401v1.full.pdf